The cross-resistance profiles of elvitegravir and dolutegravir on raltegravir-resistant variants is still controversial or not available in macrophages and lack extensive evaluations on wide panels of clonal variants. Thus, a complete evaluation in parallel with all currently available integrase inhibitors (INIs) was performed.
Introduction
Viral variants resistant to integrase inhibitors (INIs) have been detected in patients failing INI-including regimens. In particular, amino acid substitutions proximal to the catalytic core domain have been described: the E92Q, Y143R/C, N155H and Q148K/R/H mutations. 1 -4 Although mutations selected at each of these key positions are associated with therapy failure, a complex evolving pattern of primary and secondary resistance mutations has been documented during treatment with raltegravir and elvitegravir as well as after INI-based therapy interruption. 3, 5 Additional secondary mutations have been reported, including V72I, L74M, E92Q, T97A, E138A/K, G140S/A, V151I, E157Q, G163R/K and D232N. 1 -3,6 For both compounds, after selection of primary mutations, the pattern of mutations usually evolves toward a progressive increase in drug resistance and recovery of viral replication capacity.
1 -3 A more recent compound in the same class (dolutegravir) has shown a promising resistance profile on variants resistant to raltegravir or elvitegravir. 1 -3,7,8 Macrophages are an important target of HIV-1 infection and a full understanding of the anti-HIV-1 activity and pharmacology of antiretroviral drugs in macrophages is crucial in designing therapeutic strategies aimed at achieving an optimal therapeutic effect and complete eradication in all tissue compartments where the virus hides and replicates. Moreover, in the many microenvironments in which HIV-1 can infect macrophages, such as the CNS, 9 antiretrovirals are often present with significantly different antiviral activity profiles compared with circulating CD4+ T lymphocytes. 10, 11 Moreover, cell-to-cell spread may be an additional complication to achieve effective inhibitory concentrations in vivo since this modality of virus spreading may occur frequently among macrophages. 9 Studies assessing antiviral activity or cellular pharmacology of anti-HIV-1 drugs in macrophages are not available forall the recently available drugs and cannot easily be predicted from what is observed in CD4+ T lymphocytes. Little is known about the efficacy of INIs in macrophages. 12 Recent data, obtained with laboratory strains and with site-directed mutant viruses, showed that in macrophages obtained from peripheral blood mononuclear cells (PBMCs), the presence of a limited set of single primary INI resistance mutations (Q148H, Q148R, N155H, or N155S) is sufficient to provide a resistance level comparable to that associated with viruses expressing integrase with both primary and secondary mutations in CD4+ T cells. 13 These data apparently suggested that macrophages can be more prone in vivo to select resistant variants to raltegravir, leading to therapy failure. The evaluation in human macrophages of phenotypic susceptibility to dolutegravir and elvitegravir for clonal viral variants selected in vivo after an INI-based therapy failure will give crucial information on the role played by these cells in the selection of resistant viruses, and could address current gaps in our knowledge, such as regarding relative INI potency in different reservoirs, and allow for the design of drugs with even greater potency in populations of chronically infected macrophages.
Methods

Molecular cloning
Phenotypic analyses were conducted on 20 (including 7 wild-type) recombinant viruses obtained from seven HIV-1 (clade B)-infected patients failing previous raltegravir-containing regimens enrolled in the raltegravir expanded access programme (MK0518-023). Plasma samples were collected and stored at 2808C until use. After informed consent was obtained from all patients, viral RNA was extracted using the QIAamp viral RNA mini kit (Qiagen). Only one sample at a time was processed, and clinical samples and all amplification steps were conducted with a limiting dilution strategy to minimize artificial recombination events. The integrase region (codons 1 -301) was targeted using the following nested RT-PCR protocol and the following primers: Int1F, 5
′ -CATGGGTACCAGCACACACAAAGG-3 ′ and Int1R, 5 ′ -CCATGTTCTAATCCTCATCCTGTC-3 ′ for the first PCR round; and primers Int2F, 5
′ -GGAATTGGAGGAAATGAACAAGTAGAT-3 ′ and Int2R, 5 ′ -GCCACACA ATCATCACCTGCCATC-3 ′ for the second PCR round. The first nested RT-PCR reaction was performed in 50 mL using the SuperScript III Platinum High-Fidelity One-Step qRT-PCR system (Invitrogen) with the following thermal profile: 30 min at 508C and 10 min at 958C for 1 cycle, 1 min at 958C, 1 min at 528C, and 1 min and 10 s at 728C for 50 cycles, followed by 10 min at 728C. The nested reaction was performed in 100 mL using PCR SuperMix High Fidelity (Invitrogen) and the following thermal profile: 10 min at 958C for 1 cycle, 1 min at 958C, 1 min at 508C, and 1 min and 10 s at 728C for 30 cycles, followed by 10 min at 728C. 6 Amplified products were cloned into pNL(AD8)DeltaInt proviral vector 7 originally derived from an R5 (macrophage-tropic) virus. Individual clones were then sequenced using an ABI PRISM 3100 Genetic Analyser (Applied Biosystems) (GenBank accession numbers JN163873 -JN163910). Phylogenetic internal control was performed to exclude contaminations or recombination events as previously described. 14 -16 Site-directed mutants carrying single mutations G140S or Q148H were generated by reverse mutating the patient 7 clone carrying the G140S+Q148H combination, as previously described. 2 Recombinant fully replicating viruses were generated after transfection of 293T cells using Fugene6 transfection reagent (Roche), following the manufacturer's instructions. All phenotypic assays were performed as described previously with minor modifications 2, 7, 10 and the AD8 laboratory strain was used as a control.
Cell purification and phenotypic assays
Human primary monocyte-derived macrophages (M/M) were prepared and purified as described.
10 CD4+ lymphocyte and M/M used in the present study were from different blood donors. For T cells, we pooled cells from four different donors to reduce interdonor variability, while for macrophages we used single donors for each round of experiments. To avoid biases due to well-known variability in HIV replication in macrophages from different donors we performed all the phenotypic assays together in each round and repeated them in a different host, but again using all viruses together. All phenotypic assays were performed in triplicate and by using 0.001 multiplicity of infection. Briefly, M/M were obtained from the blood of healthy HIV-seronegative donors. First, PBMCs were separated by Ficoll-Hypaque gradient centrifugation and seeded in plastic 96-well plates (Costar, Cambridge, MA, USA) at a density of 0.5×10 6 cells/well in RPMI-1640 (Gibco, Gaithersburg, MD, USA) supplemented with 50 U/mL penicillin, 50 mg/mL streptomycin, 4 mM L-glutamine and 20% heat-inactivated mycoplasma-and endotoxin-free fetal bovine serum (Euroclone) (complete medium). Cell cultures were incubated in a humidified atmosphere with 5% CO 2 at 378C. Non-adherent cells were removed 5 days after seeding by repeated gentle washing with warmed RPMI-1640, leaving a monolayer of adherent cells, which were incubated in complete medium as previously described. After 2 days, seven raltegravir, elvitegravir or dolutegravir serial dilutions (from 1250 to 0.08 nM) were added to the cultures and 30 min later M/M were infected with a 150 median tissue culture infective dose of each recombinant virus. Twenty-four hours after infection the cells were gently washed with warmed PBS and incubated in complete medium containing the drug. Every week half of the medium was removed and replaced with complete medium and the appropriate drug concentration.
CD4+ lymphocytes were obtained by Ficoll-Hypaque gradient centrifugation and seeded in T25 flasks (Costar) at a density of 1.0×10 6 cells/mL in RPMI-1640 (Gibco) supplemented with 50 U/mL penicillin, 50 mg/mL streptomycin and 10% heat-inactivated mycoplasma-and endotoxin-free fetal bovine serum (Euroclone) (complete medium) supplemented with 2 mg/mL phytohaemagglutinin (PHA). After 2 days, non-adherent cells were collected and CD4+ lymphocyte were purified through an immunoaffinity column and CD4 binding antibodies (Milteny Biotec) and grown in complete medium with 50 mU/mL recombinant interleukin-2 (IL-2) in a 96-well plate (Costar). For each analysis, CD4+ lymphocytes were infected with a 100 median tissue culture infective dose of each recombinant virus. At the same time, seven raltegravir, elvitegravir or dolutegravir serial dilutions (from 1250 to 0.08 nM) were then added to the cultures. Raltegravir and dolutegravir activity were evaluated testing p24 production (Aalto Bio Reagents, Dublin, Ireland) at day 6 (CD4+ lymphocyte) or 21 (M/M) postinfection. Light units were normalized as previously described.
13 Dolutegravir was kindly provided by ViiV Healthcare (Brentford, UK), and raltegravir was provided by the National Institutes of Health AIDS reagents repository (https://www.aidsreagent.org/Index.cfm); elvitegravir was obtained as previously described. 17 
Results and discussion
Twenty fully replicating recombinant viruses bearing mutations to all primary pathways of resistance to raltegravir ( Figure 1) were generated, titrated and phenotypically evaluated in human M/M and on purified CD4+ T cells.
Phenotypic assays were conducted in parallel with raltegravir, elvitegravir or dolutegravir. A similar inhibitory concentration 50 (IC 50 ) was observed between wild-type variants and the control Canducci et al.
AD8 strain tested in purified CD4+ T cells and macrophages in our assay (Figures 2-4) . At least for raltegravir, this is different, in part, from previous reports. Marsden et al., 13 by using single-cycle experiments and laboratory strains, observed a reduced level of susceptibility to raltegravir in macrophages compared with CD4+ Tcells. Scopelliti et al., 12 by using fully replicating laboratory strains, showed instead that raltegravir was more effective in macrophages than in CD4+ T cells. These differences were not confirmed in our work by using both a laboratory strain (AD8) and seven distinct wild-type recombinant fully replicating viruses. Moreover, despite minor differences in phenotypic assays and in the kinetics of viral replication in macrophages and in CD4+ T cells, dolutegravir, elvitegravir and raltegravir resulted in an overall comparable IC 50 in both cell types when tested on virus not carrying INI resistance mutations ( Figures 2-4 and Table 1 ). This may also explain the strength of INIs in rapidly reducing HIV-1 viraemia in the plasma of patients treated with INI-based antiretroviral therapy (ART) regimens. 18 Indeed, the first and second phases of viral load decline have been associated with the distinct pharmacokinetic/pharmacodynamic properties of antiretroviral drugs on infected cell pools with different half-lives. 19, 20 Our data support the idea that raltegravir, elvitegravir and dolutegravir are indeed highly and equally effective on both major sources of HIV-1 during both viral decay phases.
For all clones with raltegravir-associated resistant mutations, the IC 50 fold change (FC) resistance levels were also calculated. Integrase inhibitors in macrophages or lymphocytes 2527 JAC As previously described, Y143R single mutants conferred a higher level of raltegravir resistance in macrophages (FC 47.7 -60.24) compared with CD4+ T cells (FC 9.55 -11.56), while the N155H single mutant had comparably high raltegravir resistance levels in both cell types (FC 37.54-47.78) (Figure 4a ). This observation may suggest that in those patients failing raltegravir with these pathways (in particular, with Y143R, which affects resistance differently in lymphocytes and macrophages), selection could have occurred in macrophages that apparently do not need secondary or compensatory mutations to significantly increase FC resistance to raltegravir. However, it can also be speculated that the pharmacodynamics of raltegravir with viruses bearing these mutations are affected differently in the two cell types. Indeed, elvitegravir, dolutegravir and raltegravir have distinct dissociation rates with INI-resistant viral integrases, 21 and it cannot be excluded that within distinct intracellular environments this phenomenon may be responsible in part for the enhanced level of resistance of single mutants. Of note, as seen by the relative dissociation rates Figure 3 . Antiretroviral activity of INIs in monocytes/macrophages on raltegravir-resistant recombinant viral variants bearing primary and secondary mutations in the Q148H pathway of resistance. For each patient the IC 50 of the wild-type (WT) recombinant virus obtained from samples collected before raltegravir therapy was also evaluated. Phenotypic evaluation was also performed on site-directed single mutants (*) of clones from patient 7. The Q148H single mutants replicated at very low levels (with an estimated 80% reduction in viral RC) and IC 50 could not be reliably calculated in macrophages.
Canducci et al. Integrase inhibitors in macrophages or lymphocytes these macrophage cells; either or both of these factors might facilitate an effect such as this. To further evaluate the role of single mutants on the phenotypic susceptibility to INIs, we generated Q148H and G140S recombinant viruses from a patient 7 clone bearing the Q148H + G140S combination. Both single mutants had a reduced replication capacity (RC) as estimated by parallel growth kinetics (data not shown). The reduction in RC was so important in macrophages ( 80% reduction) that phenotypic susceptibility could not be reliably calculated for the Q148H mutation. Interestingly, the single mutants carrying this mutation were not associated with a reduction in dolutegravir susceptibility in CD4+ T cells as previously shown for site-directed mutants in laboratory strains. 22 In patient 5, a clone amplified at therapy failure and carrying only the Q148R+ G140S combination similarly had a very low RC in macrophages (in part also in CD4+ lymphocytes, where a 50% reduction in RC was observed) and IC 50 could not be estimated accurately. The G163R mutation rescued the RC in this variant (Table 1 and Figure 4b ).
All the other combinations including Y143R/C(+/2T97A) or Q148H/R(+/2G140S+/2G163R) had similar effects on viral susceptibility to raltegravir or elvitegravir in both cell types ( Figure 4 and Table 1 ). However, while with elvitegravir a similarly high level of reduction in susceptibility was observed for both the N155H and the Q148H/R pathways, none to modest (4.8 FC for the Y143C variant) increases were observed for the Y143R/C pathways, in agreement with recently published results. 23 This is an important point, since elvitegravir will probably be the next INI to be marketed, and these data suggest that only partial residual activity on Y143R-bearing viruses can probably be expected. However, in the many microenvironments in which HIV-1 can infect macrophages, other antiretroviral drugs can have different activity profiles compared with circulating CD4+ T cells, and this may limit the overall genetic barrier of the antiretroviral regimen and compromise the long-term efficacy of elvitegravir-based (or raltegravirbased) regimens despite its efficacy in these cell types.
Interestingly, dolutegravir maintained its activity and crossresistance profile in macrophages with IC 50 s and FCs comparable to those previously observed in CD4+ T cells. In particular, only Q148H/R-bearing variants were associated with a reduced level of susceptibility , while no variations from wild-type were observed for variants with Y143R/C (+/2T97A) or N155H mutations.
Conclusions
These data demonstrate that all INIs have overall comparable antiretroviral activity in both cell types even if single mutations showed a different impact on the level of susceptibility in lymphocytes and in macrophages. In particular, we showed that dolutegravir is capable of inhibiting infection of raltegravir-resistant variants with Y143 or N155 pathways of mutations in both macrophages and CD4+ T cells with comparable potency, and suggest that the sequential use of dolutegravir may not be affected by phenotypic profiles of raltegravir-resistant variants archived in macrophages, which may be significantly different from those observed in circulating CD4+ T cells.
